Randomized trial compares survival outcomes in ovarian cancer patients receiving surgery or chemotherapy, suggesting differing survival factors.
Key Points
This study aims to compare survival factors between patients receiving neoadjuvant chemotherapy and those undergoing primary surgery for advanced ovarian cancer.
GOG-262 was a prospective randomized trial evaluating dose dense chemotherapy.
Physicians could choose between primary debulking surgery and neoadjuvant chemotherapy.
Chi-squared tests and Kaplan-Meier procedures were used for analyses.
Of 192 patients, 119 (62%) underwent primary debulking surgery and 73 (38%) received neoadjuvant chemotherapy.
5-year overall survival was 47.8 months for primary surgery vs. 41.9 months for neoadjuvant chemotherapy (P = .75).
Advanced disease stage IV and peritoneal cancer type were associated with poorer survival outcomes.